The Q3 report card of multinational pharmaceutical companies has been announced: Merck’s growth rate is unique, Novartis clamors that China’s sales will double, and Aber Maintenance Miller is gradually losing its color...

According to statistics from E-pharmaceutical managers, as of today, ten large multinational pharmaceutical companies including Novartis, Merck, Roche, GSK, BMS, Johnson & Johnson, Sanofi, AbbVie, Eli Lilly and Gilead have released their 2021 Third quarter earnings report
.

Among them, Merck has a growth rate of 20%.

Novartis: Doubles sales in China by 2024

Novartis: Doubles sales in China by 2024

Novartis is on the eve of its rise, but faces difficult choices
.

Its latest financial report shows that Novartis' innovative drugs and generic drugs show different situations
.

In the third quarter, Novartis achieved net sales of US$13.

Is Sandoz a drag on Novartis? Should he bear the pain of giving up?

Novartis pointed out that the company has already begun a strategic review of Sandoz to determine whether it is still suitable for Novartis' long-term growth plan
.

The company’s CEO Vas Narasimhan said, “Although Sandoz generated $9.

A set of data in the financial report also shows Novartis' "hesitation": the sales of generic drugs in the next 10 years will be US$400 billion, and biosimilar drugs will be US$170 billion, with a compound annual growth rate of 9%
.

And Sandoz ranks first in Europe and ranks among the top five in all major regions

For a long time, Novartis has been criticized for lack of super blockbuster new drugs, but such new drugs are hard to find.
The era of single product dominance has passed, and more flowering is king
.

Nowadays, many drugs have supported Novartis’s innovative growth.

In China, Novartis’ sales in the third quarter reached US$839 million, a year-on-year increase of 18%
.

But it is not satisfied to stop here in China.

Novartis laid out three reasons.
First, the existing products can be well maintained, Nuoxinto's stock sales are stable, and the sales growth of all key products that have entered the medical insurance catalog has exceeded that of other multinational pharmaceutical companies
.

At the same time, Novartis has strengthened its activities in second- and third-tier cities and hospitals, and the impact of centralized procurement is limited

MSD: Where is the next growth point for winning the battle of PD-1?

MSD: Where is the next growth point for winning the battle of PD-1?

The successful commercialization of PD-1 and HPV vaccines, one is a tens of billions of bombs, and the other is a potential of tens of billions of bombs.
These two achievements of Merck are enough to make him successful
.

But apart from these two heavyweight single products, there is no potential relay product among its existing products
.

Where is the next growth point for Merck?

In the third quarter of 2021, revenue of 13.
2 billion U.
S.
dollars, an increase of 20% year-on-year, Merck & Co.
is outperforming multinational pharmaceutical companies
.

Among them, Keytruda has sales of US$4.
5 billion, accounting for 34% of its overall revenue
.
Sales of HPV vaccines approached US$2 billion, an increase of 68% year-on-year
.
The sales contribution ratio of these two heavyweight products is close to 50%
.

The performance of the other varieties was mixed, with the increase generally not exceeding 20%
.
Merck is clearly aware of the current situation.
The first task of the new CEO Robert Davis is to help Merck find the next growth point
.

In 2021, Merck has increased its acquisition of late-stage clinical drugs, supplementing and expanding its pipeline in cardiovascular and other fields
.
At the same time, Merck is also extensively developing early research and development cooperation with Biotech on new technologies
.
At the recent Q3 earnings conference, Robert admitted: Merck will conduct more mergers and acquisitions, including large-scale mergers and acquisitions
.
"We believe that we have the ability to make any transaction
.
If there is a good opportunity, we will make a transaction
.
"

AbbVie: Xiu Mei Le is gradually "fading", where is the successor?

AbbVie: Xiu Mei Le is gradually "fading", where is the successor?

The seven-year medicine king may no longer be brilliant from this year
.
AbbVie has no Xiu Mei Le, what's left?

In the first three quarters of 2021, AbbVie achieved US$14.
342 billion in revenue, an increase of 11% year-on-year, which is the average among multinational pharmaceutical companies
.
Among them, the sales of Xiu Meile were US$5.
425 billion, a year-on-year increase of 5.
6%, accounting for 37.
8% of the overall business revenue
.
Humira’s net income in the United States was US$4.
613 billion, an increase of 10.
1%; due to competition from biosimilars, Humira’s international net income fell to US$812 million, a decrease of 16.
7% on an operating basis
.

The decline in the international market after the expiration of patents will be something that Humira America will face in the next few years, and it is also a crisis for AbbVie's entire company.
Some professionals say that adalimumab biosimilars will enter as early as 2023.
The impact of the US market on AbbVie can be referred to the international market
.

However, AbbVie is already weakening its dependence on Xiumile.
In 2020, Xiumile’s contribution rate to revenue is 43%, and now it is 37.
8%
.
However, the performance of its existing products is not very good, another blockbuster new drug Imbruvica in the third quarter sales of 1.
374 billion US dollars, almost no increase from the previous year
.

In addition, recently the FDA will add more safety warnings and restrict the use of JAK inhibitors, and industry professionals have begun to weigh the impact of this news on AbbVie's Rinvoq
.
AbbVie said that restricting the use of Rinvoq after TNF inhibitors will harm Rinvoq in the short term, especially considering that the drug has already acquired some first-line patients
.

The above-mentioned potential products may grow weakly or encounter potential crises.
What should AbbVie do?

BMS: Performance continues to rebound, and challenges may be met next year

BMS: Performance continues to rebound, and challenges may be met next year

In the third quarter of 2021, Bristol-Myers Squibb’s performance revenue reached 11.
62 billion U.
S.
dollars, compared with 10.
54 billion U.
S.
dollars in the third quarter of last year, an increase of 10% year-on-year
.

BMS said that the company has strong market demand in all four key therapeutic areas.
Among them, sales in the US market increased by 12% from last year to 7.
3 billion U.
S.
dollars, and international revenue reached 4.
3 billion U.
S.
dollars, an increase of 8% year-on-year
.

Revlimid (lenalidomide), Eliquis (apixaban), Opdivo (nivolumab) and the latest product portfolio became the main driving factors driving its revenue growth
.

The three major products have achieved global growth.
The sales of lenalidomide reached US$3.
34 billion, a year-on-year increase of 11%; the sales of Apixaban Q3 reached US$2.
41 billion, a year-on-year increase of 15%; the sales of O drug It also reached 1.
9 billion US dollars, an increase of 7% year-on-year
.

BMS CEO Giovanni Caforio also said that the company's strong performance in the third quarter reflected the "continuous growth in demand in the four core therapeutic areas" as well as the "increased use of new product portfolios
.
"

BMS’s world’s first BCMA CAR-T therapy, Abecma, was approved for the treatment of multiple myeloma in the United States and Europe earlier this year, with sales of US$71 million in the third quarter, up from US$24 million in the second quarter
.
Breyanzi, another CD19CAR-T cell therapy, achieved sales of US$30 million in the third quarter, higher than the US$17 million announced earlier this year
.

BMS said that in the third quarter of 2021, research expenses increased by 30% year-on-year to US$3.
3 billion.
In addition, BMS also announced the latest developments in the R&D pipeline
.

What BMS emphasized is that another part of the reason for the sales of new products and the connecting pipeline comes from the patent protection of lenalidomide which will expire next year.
The outside world is generally worried that the expiration of the patent of BMS's most important drug will have a huge impact on its future sales.

.

Gilead: Remdesivir has sold more than 1.
9 billion US dollars, how long can we rely on it?

Gilead: Remdesivir has sold more than 1.
9 billion US dollars, how long can we rely on it?

In the third quarter of 2021, Gilead’s revenue reached US$7.
356 billion, a year-on-year increase of 13%
.

The growth is due to the sales of remdesivir, the "new crown drug".
Remdesivir was approved by the FDA in October 2020, becoming the first officially approved new crown treatment drug in the United States
.
Since then, sales have soared all the way, and the United States accounted for most of its sales
.
Gilead said that in the third quarter of 2021, sales reached US$1.
923 billion, a year-on-year increase of 121%; the first three quarters totaled US$4.
208 billion, a year-on-year increase of 382%
.

But beyond that, the situation in other business lines of Gilead is not optimistic
.
After excluding Remdesivir, the sales of Gilead’s other products in Q3 were only US$5.
433 billion, a year-on-year decrease of 3%
.

HIV-related products, which accounted for more than half of Gilead’s revenue, achieved sales of US$4.
189 billion, a year-on-year increase of only 8%
.
Although the new three-in-one compound drug Biktarvy increased significantly by 20% year-on-year and achieved sales of US$2.
276 billion, Truvada (down 87%), Descovy (down 15%), Genvoya, and Atripla

(Down 76%) and other products have experienced sales declines of different magnitudes
.
In the first three quarters of 2021, Gilead’s HIV product sales totaled US$11.
77 billion, a year-on-year decline of 7.
1%
.

In other antiviral fields, the sales of chronic hepatitis C virus (HCV) drugs were US$429 million, a year-on-year decrease of 8%; the sales of hepatitis B virus (HBV) and hepatitis D virus (HDV) drugs were US$247 million, a year-on-year increase of 17%
.
The new hepatitis B drug Vemlidy increased by 18% year-on-year, achieving sales of US$208 million
.

In cell therapy, Gilead achieved a growth of 51%, with sales reaching US$222 million
.
CD19 CAR-T cell therapy Yescarta achieved sales revenue of US$175 million, a year-on-year increase of 26.
8%
.

The ADC drug Trodelvy, which was approved for marketing in April 2021, also achieved rapid growth, with sales reaching 101 million U.
S.
dollars in the third quarter
.

Although there are many products that have achieved growth, Gilead’s current performance growth is overly dependent on Radixivir.
The outside world is worried about how long Gilead can rely on this "new crown medicine" as the new crown epidemic gradually flattens out?

Sanofi: Growth of over 50%, strong performance in the Chinese market

Sanofi: Growth of over 50%, strong performance in the Chinese market

In the third quarter of 2021, Sanofi’s revenue reached 10.
432 billion euros (approximately 12 billion U.
S.
dollars), a year-on-year increase of 10.
1%
.

CEO Paul Hudson said that the double-digit growth was due to Dupixent's outstanding performance, record sales of vaccines and the growth momentum of the Consumer Healthcare Business (CHC)
.

Dupixent was jointly developed by Sanofi and Regeneron Pharmaceuticals for the treatment of atopic dermatitis and asthma.
It has been one of the main driving forces of Sanofi's performance after its listing
.
In the third quarter of 2021, global sales increased by 53.
6% year-on-year to 1.
4 billion euros, of which 47.
7% in the United States and 78.
4% in Europe
.
Dupixent's sales have nearly tripled in the past two years, and the relevant person in charge of Sanofi predicts that this year's annual sales will reach 6 billion euros
.

In addition, Sanofi's global revenue in the vaccine business increased by 16.
5% year-on-year, reaching 2.
422 billion euros; CHC business sales were 1.
155 billion euros, an increase of 11.
1% year-on-year
.

Another point worth noting is that in the third quarter of 2021, Sanofi's revenue in the Chinese market was 782 million euros, a year-on-year increase of 12.
8%
.
Second only to the fastest-growing markets in Brazil and the United States, their sales in the third quarter increased by 14.
8% and 13.
4%, respectively
.

Dupixent has also performed strongly in China.
In addition, insulin glargine, which was approved for marketing in June 2020, has also achieved growth in products such as clopidogrel, an anticoagulant drug that has been included in the post-harvest sales recovery
.

In the field of vaccines, its flu vaccine and five vaccines Pan Taixin (diphtheria, tetanus, pertussis, polio and Haemophilus influenzae type b vaccines) continue to create good results in the Chinese market
.

In the first three quarters of 2021, Sanofi’s total sales revenue in the Chinese market reached 2.
162 billion euros, an increase of 8.
5% year-on-year
.

Roche Pharmaceuticals: There are good and bad news for new crown drugs

Roche Pharmaceuticals: There are good and bad news for new crown drugs

The new crown epidemic is like a double-edged sword for Roche
.

Its financial report for the third quarter of 2021 showed that due to the impact of the new crown epidemic, Roche's pharmaceutical division saw a negative growth in revenue in the first quarter of 2021, which was -9%
.
In the second quarter, it improved slightly, with an increase of 4%, and a 5% increase in the third quarter.
Revenue in the third quarter was 11.
8 billion Swiss francs (approximately US$12.
9 billion), which was almost the same as last year
.

In terms of drug sales, Hemlibra has become the fastest-growing product among Roche's Top 10 products in the first three quarters of 2021 with a sales growth rate of 42% year-on-year
.
And Ocrevus (Ocrevus) became the number one with sales of 3.
721 billion Swiss francs
.

Although Roche is not as prominent as Pfizer in the development of the new crown vaccine, it has done a good job in the expansion of drug indications
.
Its IL-6 monoclonal antibody tocilizumab (Actemra) for the treatment of immune diseases has received emergency use authorization from the FDA and recommended by the WHO for the treatment of cytokine release syndrome in hospitalized patients with new coronary disease, and its sales have also increased by 57%.

.

The new crown oral drug AT-527, which announced the failure of phase II clinical trials last week, did pour cold water on Roche
.
After all, Molnupiravir, which is also an oral drug for the new crown, has already been submitted to the FDA for emergency use authorization by Merck in early October
.
In the face of the failure of new crown drug development, Roche did not say much, but it is foreseeable that he will not give up easily
.

Eli Lilly: Or enter the "period of profit growth that lasts until 2030"?

Eli Lilly: Or enter the "period of profit growth that lasts until 2030"?

In the third quarter of 2021, Eli Lilly’s sales reached US$6.
373 billion, a year-on-year increase of 18%
.
Excluding the sales impact caused by the new crown antibody, sales in the third quarter of 2021 and the first three quarters of 2021 both increased by 11% year-on-year
.

Among them, the revenue of several key growth products, the diabetes drug Trulicity, the immunological blockbuster Taltz, the breast cancer treatment Verzenio, and the migraine prevention antibody Emgality, all increased by more than 30% year-on-year
.

Due to the increase in revenue, the company's earnings per share also rose to $1.
94, an increase of 38% compared to the same period last year, but still slightly lower than Wall Street's previous forecast of $1.
96 per share
.

"Lilly once again achieved a strong performance this quarter
.
The sales revenue of new products increased by 35%, accounting for nearly 60% of its core business.
This strongly signifies the huge potential of Lilly's long-term development in the future
.
" Director of Eli Lilly Pharmaceuticals Said David Ricks, Chief Executive Officer
.

On October 26, Eli Lilly used the priority review voucher to file an application for tirzepatide for the treatment of type 2 diabetes to the US regulatory agency
.

The importance of the drug to Eli Lilly is self-evident, and it is also another trump card for the company to maintain its position in the diabetes drug market after dulaglutide
.
According to the US FDA's priority review procedures and timetable, Eli Lilly expects that it will take about 8 months from the submission of the tirzepatide application to the approval of the market, which also means that at the end of June 2022, Eli Lilly can usher in the approval of tirzepatide
.

At the same time, the company has also begun rolling submissions to the FDA for accelerated approval of donanemab for the treatment of early-stage Alzheimer's disease
.
Previously, the US FDA has granted Alzheimer's drug donanemab breakthrough therapy designation
.

David Ricks believes that Eli Lilly has advanced a series of potentially best-in-class innovative therapies, covering multiple areas with unmet needs, and will have the potential to continue to bring products to more patients in the future
.

Analysts also predict the future as the number of first-class product line pipe order is approved, Lilly is expected to enter into "profit growth period until 2030"
.

GSK: Rapid increase in new products, offsetting decline in mature drugs

GSK: Rapid increase in new products, offsetting decline in mature drugs

In the third quarter of 2021, GlaxoSmithKline (GSK) achieved sales revenue of 9.
077 billion pounds (approximately US$12.
4 billion), a year-on-year increase of 13%
.

In this regard, GSK CEO Emma Walmsley said, “GSK has achieved a strong business performance in a single quarter, with sales of pharmaceuticals and vaccines achieving double-digit growth
.
”

In the third quarter of 2021, GSK's pharmaceutical industry turnover was 4.
397 billion pounds, a year-on-year increase of 10%.
This increase was mainly due to the strong growth of its new products, which partially offset the decline in sales of mature drugs
.
Among them, sales of new products reached 2.
475 billion pounds, an increase of 24%, and continued growth in the treatment of respiratory, tumor, immune inflammation and HIV
.

Driven by the triple inhalation preparations Trelegy (flutimavir) and Nucala (mepolizumab), the sales revenue of respiratory products reached 741 million pounds, an increase of 33% year-on-year, of which flutimavir increased by 85%
.

The total sales income of HIV drugs was 1.
251 billion pounds, an increase of 8% year-on-year, mainly due to the growth of new products such as Dovato, Juluca, Rukobia, and Cabenuva, which together accounted for 29% of HIV drug sales
.

In the field of oncology, affected by the approved indications for the treatment of ovarian cancer, the sales of PARP inhibitor Zejula (Ze Le, Nirapali) in the quarter were 101 million pounds, an increase of 15%
.

Sales in the area of ​​immune inflammation were 241 million pounds, an increase of 25% year-on-year, of which Benlysta (belimumab) sales increased 28% year-on-year to 238 million pounds
.

GSK's vaccine division achieved sales of 2.
174 billion pounds in Q3 of 2021, an increase of 13% year-on-year.
GSK said it was mainly due to the growth in sales of the shingles vaccine Shingrix in the United States and Europe and the promotion of pandemic adjuvant sales.

.
Xin'anli is suitable to be approved for listing in China in July 2020, and it is also one of the first batch of 48 "clinical urgently needed new drugs" that have been marketed overseas that have been quickly introduced in China
.

Johnson & Johnson: The pharmaceutical business grows, and the rise and fall are at the same time

Johnson & Johnson: The pharmaceutical business grows, and the rise and fall are at the same time

In the third quarter of 2021, Johnson & Johnson’s sales were USD 23.
338 billion, a year-on-year increase of 10.
7%, of which the pharmaceutical business achieved sales revenue of USD 12.
994 billion, a year-on-year increase of 13.
8%
.

Immunotherapy is the treatment field with the highest sales revenue of Johnson & Johnson, reaching US$4.
25 billion in the third quarter, a year-on-year increase of 12.
2%; the oncology field achieved sales revenue of US$3.
665 billion, a year-on-year increase of 17.
1%; the nervous system field achieved US$1.
689 billion, a year-on-year increase of 5.
3%.
%; Infectious disease field was 1.
389 billion US dollars, an increase of 60.
6%; cardiovascular and other metabolic fields were 1.
113 billion US dollars, a year-on-year decrease of 11.
5%; hypertension field was 868 million US dollars, a year-on-year increase of 15.
9%
.

Johnson & Johnson's financial report shows that in the third quarter of 2021, a number of drugs have achieved more than double-digit growth.
Among them, the prostate cancer drug Erleada (apatamide) increased by 66.
7% year-on-year the fastest, with sales reaching 344 million U.
S.
dollars; Tremfya (gusecuzumab) increased by 64.
1% year-on-year and sales reached 537 million U.
S.
dollars; Darzalex (daratumumab) increased by 43.
7% year-on-year, and sales reached 1.
58 billion U.
S.
dollars; Stelara (usnumab) was US$2.
378 billion, a year-on-year increase of 22.
2%; Opsumit's sales in the third quarter were US$458 million, a year-on-year increase of 17%
.

On the other hand, Remicade (infliximab), Invokana (canagliflozin), Zytiga (abiraterone acetate) and other drugs have experienced a sharp decline
.
The sales of hypoglycemic drugs in the United States in the third quarter of 2021 were only US$66 million, a decrease of 57.
4% year-on-year; under the strong impact of biosimilar drugs, the sales of infliximab in the US fell by 24.
3% to only US$480 million.
In the global market, it also fell by 17.
4% to 761 million US dollars; Abitron’s sales in the United States were only 25 million US dollars, down 57% year-on-year, and global market sales were 548 million US dollars, down 7.
2% year-on-year
.